Navigation Links
Landmark ONTARGET(TM) Trial Demonstrates Micardis(R) is Equally Effective as Ramipril, with Fewer Discontinuations, in a Broad High-Risk Cardiovascular Population
Date:3/31/2008

iabetes, cognitive decline/dementia, nephropathy, atrial fibrillation and left ventricular hypertrophy.

Treatment arms for the ONTARGET(TM) trial were telmisartan 80 mg, ramipril 10 mg and a combination therapy with telmisartan 80 mg and ramipril 10 mg. All treatments were applied in addition to standard care for high-risk cardiovascular patients.

More than 700 sites throughout Asia, Australia, New Zealand, Europe, North/South America and South Africa participated in the ONTARGET Trial Program. The ONTARGET Steering Committee consists of scientists from McMaster University in Ontario, Canada; Oxford University in Oxford, England; the University of Auckland in Auckland, New Zealand; and Boehringer Ingelheim.

The ONTARGET trial was investigational and was conducted to expand scientific knowledge of telmisartan. Note that the trial included treatment for conditions outside the approved indication for telmisartan.

About Cardiovascular Disease

Cardiovascular disease (CVD) is the number one cause of death and disability globally(4) and is responsible for one of every three deaths worldwide -- an estimated 17 million people per year.(5) CVD causes more deaths than cancer, chronic respiratory disease and diabetes combined.(6) By 2020, it is predicted that CVD will surpass infectious diseases to become the largest cause of death and disability worldwide.(7) It is also contributes significantly to the escalating costs of health care. In 2006, the cost of CVD in the U.S. was estimated at $403.1 billion.(8)

Boehringer Ingelheim and Cardiovascular Medicine

Boehringer Ingelheim continues its century-long history of innovation and commitment to continuing research to further understand cardiovascular disease -- the number one cause of death worldwide. Boehringer Ingelheim has introduced novel agents in the management of hypertension and treatment of secondary stroke and continues to invest in a comprehensive cardiovascular pipeline.
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
2. Viatronix V3D-Colon Utilized in Another Landmark Study
3. Long-Term Data from a Landmark Phase III Trial Show Survival Benefit at Three- and Four-Years in Patients with Glioblastoma multiforme
4. Hospital Launches Landmark Emergency Medicine Project
5. JACC Identifies DEFER with 5-year Outcomes as Landmark Trial
6. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
7. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
8. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
9. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
10. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... , Dec. 19, 2014 In ... a product,s web presence to reflect the needs ... in particular, must meet the needs of key ... culture. According to recent research ... half of the participating companies averaged more than ...
(Date:12/19/2014)... 2014  Monarch America Inc. (OTCQB: CANK) ("Monarch America" ... to provide this review of the Company,s recent achievements ... "Over this past year, we achieved many of ... proud to say that Monarch America is in a ... ever been," stated Eric Hagen , CEO of ...
(Date:12/19/2014)... , December 18, 2014 ... software application/module that is used to store, manipulate, ... RIS comprises a patient tracking and scheduling system, ... integration of RIS with HIS and other databases ... patient registration and patient scheduling, patient list management, ...
Breaking Medicine Technology:Building a Best-in-Class Pharma Global Brand Website 2Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 2Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 3The Global Radiology Information Systems Market is Expected to Grow at a CAGR of 7.5% from 2014 to 2019 2The Global Radiology Information Systems Market is Expected to Grow at a CAGR of 7.5% from 2014 to 2019 3
... 2007--Sciele Pharma, Inc.,(NASDAQ:SCRX) today announced the successful completion ... formulation. The study,results showed that the new Sular ... new Sular formulation,utilizes SkyePharma's (LSE:SKP) patented Geomatrix technology,which ... Sular for each of its,current doses. , The ...
... Calif.--(BUSINESS WIRE)--May 14, 2007 - Oculus Innovative,Sciences, ... was the subject of a poster presentation ... that was held in,Glasgow, Scotland this past ... an Antimicrobial,Solution in the Treatment of Infected ...
Cached Medicine Technology:Sciele Pharma Announces Successful Completion of New Sular,Formulation Clinical Trial Program 2Sciele Pharma Announces Successful Completion of New Sular,Formulation Clinical Trial Program 3Sciele Pharma Announces Successful Completion of New Sular,Formulation Clinical Trial Program 4Oculus Innovative Sciences Microcyn Technology Presented in Poster,at European Wound Management Association Conference 2Oculus Innovative Sciences Microcyn Technology Presented in Poster,at European Wound Management Association Conference 3
(Date:12/19/2014)... These vanadium reserves are mostly found ... 151,000 tons of vanadium were produced globally in 2013, ... increased at 6.7% AAGR during the period from 2001 ... being the largest consumer, accounted for more than 90% ... alloy and the chemical industry. , View Full Report ...
(Date:12/19/2014)... Dec. 19, 2014 (HealthDay News) -- New research warns parents that ... lives at risk. Nearly half of teen drivers killed in ... were at least 11 years old and often lacked important safety ... Eighty-two percent of teen drivers killed in crashes were in cars ... to 10 years old, 31 percent were in cars 11 to ...
(Date:12/19/2014)... FRIDAY, Dec. 19, 2014 (HealthDay News) -- Injectable drug ... double the suicide attempt rate of other substance users, ... use is associated with the risk of suicide attempt ... the University of Montreal, said in a university news ... users. We wanted to know who among substance users ...
(Date:12/19/2014)... NC (PRWEB) December 19, 2014 Surviving Mesothelioma ... and EPA information indicates that these pipes can leach asbestos ... go to the full story on the Surviving Mesothelioma ... the erosion of natural asbestos deposits, decaying water mains made ... drinking water. , To protect consumers from mesothelioma ...
(Date:12/19/2014)... (PRWEB) December 19, 2014 B. E. ... to healthcare providers, has been retained to lead a ... Memorial Hospital in Franklin, Ind. The top executive search ... recently placed more than 900 healthcare executives into organizations. ... full service hospital providing care to the residents of ...
Breaking Medicine News(10 mins):Health News:Marketresearchreports.biz: Global Vanadium Usage Increased at AAGR of 6.7% between 2001 and 2013 2Health News:Marketresearchreports.biz: Global Vanadium Usage Increased at AAGR of 6.7% between 2001 and 2013 3Health News:Older Cars a Bad Choice for Younger Drivers 2Health News:Cocaine, Amphetamines May Up Injection Drug Users' Suicide Risk 2Health News:Surviving Mesothelioma Warns of Potential Mesothelioma Risk from Cement Water Pipes 2Health News:Johnson Memorial Hospital Retains B. E. Smith to Recruit New Chief Financial Officer 2Health News:Johnson Memorial Hospital Retains B. E. Smith to Recruit New Chief Financial Officer 3
... along with commonly used medications may help ease ... for breast cancer patients, if researchers at National ... , , ,According to Dr. Joannieshen MD, MPH, ... in controlling vomiting than just medication.Ian Cyrus, Director ...
... children of a lesser God. The physical, mental, moral ... One stumbling handicap in the surgical treatment of such ... children. In many cases the anesthesia times ranged from ... placement to hemispherectomy. There is however light at ...
... heart attack patients should get an immediate procedures to open ... ,Cleveland Clinic cardiologist, Dr. Deepak Bhatt analyzed medical records ... patients whose white blood cell count is in what is ... of death after a heart attack than patients with lower ...
... uncommon problem due to the hot and often humid weather. Most ... The cause of stone disease is debatable, however it is ... stone disease. , ,New research by the National Kidney ... Nano bacteria., ,These bacteria use a protective covering made of ...
... 8-center study by "Childhood Asthma Management Program" (CAMP) has ... the long-term treatment of children with mild to moderate ... the effectiveness of inhaled corticosteroids in treating asthma, their ... questions have been raised about their possible effects on ...
... and many a times the diagnosis is made by ... a promising technique for early diagnosis of Urinary Tuberculosis. ... amplification of small amounts of a genome sequence, Dr ... Congress in India. Presence of even one bacteria can ...
Cached Medicine News:Health News:Inhaled Steroids Safe & Effective for Children with Asthma 2
Full Handle Laseredge Slit Blade Knife, 3.0 mm straight. Blade tip dimension: 14.4 mm x 3.0 mm x 3.7 mm....
Full Handle Laseredge Slit Blade Knife, 2.65 mm angled bevel up. Blade tip dimension: 14.4 mm x 2.65 mm x 3.7 mm....
Full Handle Laseredge Implant Blade Knife, 3.2 mm round tip. Blade dimension: 14.4 mm x 3.2 mm x 3.8 mm x 1.65 mm....
Full Handle Laseredge Implant Blade Knife, 4.0 mm straight. Blade dimension: 15.2 mm x 4.0 mm x 3.0 mm x 1.6 mm....
Medicine Products: